Authors’ Disclosures
cancer, P., Cancer
VIRUS, CANCER, VACCINIA, MUTANTS, NEWCASTLE DISEASE, ONCOLOGY, CANCER
P.B. Chapman reports grants from NCI during the conduct of the study; personal fees from Merck, Pfizer, Black Diamond, Gigagen, and other from Rgenix outside the submitted work. M.A. Postow reports grants and personal fees from BMS, Merck; personal fees from Chugai, Nektar, and Pfizer outside the submitted work. A.N. Shoushtari reports grants and personal fees from BMS, Novartis; personal fees from Erasca; grants from Immunocore, Pfizer, Targovax, Alkermes, Checkmate Pharmaceuticals, Foghorn Therapeutics, Linnaeus Therapeutics, Prelude Therapeutics, and Iovance Biotherapeutics outside the submitted work. R.J. Sullivan reports grants and personal fees from Merck; personal fees from Novartis, Pfizer, and BMS outside the submitted work. J.D. Wolchok reports personal fees from Apricity, CellCarta, Ascentage Pharma, Astellas, Bicara Therapeutics, Boehringer Ingelheim, Daiichi Sankyo, Dragonfly, Georgiamune, Imvaq Therapeutics, Larkspur, Maverick Therapeutics, Psioxus, Tizona therapeutics, Sellas, Arsenal IO, Beigene, Linneaus, and Trieza Therapeutics; grants and personal fees from Bristol Myers Squibb; other from Recepta; grants from Sephora outside the submitted work; in addition, J.D. Wolchok has a patent to Xenogeneic DNA Vaccines (licensed and with royalties paid), a patent to Newcastle Disease viruses for Cancer Therapy (licensed and with royalties paid), a patent to MDSC assay (licensed and with royalties paid), a patent to PREDICTION OF RESPONSIVENESS TO TREATMENT WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF (licensed and with royalties paid), a patent to Anti-PD1 Antibody (licensed and with royalties paid), a patent to Anti-CTLA4 antibodies (licensed and with royalties paid), a patent to Anti-GITR antibodies and methods of use thereof (licensed and with royalties paid), a patent to Vaccinia virus mutants useful for cancer immunotherapy issued, and a patent to D40 BINDING MOLECULES AND USES THEREOF issued. T. Merghoub is a consultant for Daiichi Sankyo, Leap Therapeutics, Immunos Therapeutics, and Pfizer and co-founder of Imvaq Therapeutics. T. Merghoub has equity in Imvaq Therapeutics. T. Merghoub reports grants from Bristol Myers Squibb, Surface Oncology, Kyn Therapeutics, Infinity Pharmaceuticals, Peregrine Pharmaceuticals, Adaptive Biotechnologies, Leap Therapeutics, and Aprea. T. Mergghoub is an inventor on patent applications related to work on oncolytic viral therapy, alpha virus-based vaccine, neoantigen modeling, CD40, GITR, OX40, PD-1, and CTLA-4. P. Wong reports personal fees from Leap Therapeutics outside the submitted work. No disclosures were reported by the other authors.